🕒 Last update: loading…16/11/2026

Stock Allogene Therapeutics, Inc. ALLO

Allogene Therapeutics, Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -3.53%

Price change 2019 → 2020: -2.85%

Price change 2020 → 2021: -40.89%

Price change 2021 → 2022: -57.84%

Price change 2022 → 2023: -48.97%

Price change 2023 → 2024: -33.64%

Price change 2024 → 2025: -35.68%

Price change 2025 → 2026: -13.87%

Price change 2026 (year to date): -12.59%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.28

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -1.76

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 49.36% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Allogene Therapeutics, Inc.–0.28–🔒
Boiron S.A.13.20.08−0.2 %–
LNA Santé S.A.10.72.75+10.4 %–
Valerio Therapeutics S.A.–3.67−13.5 %–
Eurobio Scientific S.A.36.90.09+22.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Allogene Therapeutics, Inc. over the latest fiscal years.

Revenue
22,000 USD
fiscal year 2024
Net income
-258 m USD
fiscal year 2024
Net margin
-1,170,863.6 %
fiscal year 2024
Market cap
291 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2021114 m-182 m-159.6 %n/a
2022156,000-340 m-218,214.1 %-99.9 %
202395,000-327 m-344,489.5 %-39.1 %
202422,000-258 m-1,170,863.6 %-76.8 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Allogene Therapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-4.92
risk zone (below 1.81)
Piotroski Score
2 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.24 x
net cash
Fiscal year20212022202320242025
Cash and investments457 m517 m449 m292 m250 m
Total Debt73.1 m101 m95.1 m90.8 m83.3 m
Net Debt-100 m39.2 m12.0 m15.5 m31.6 m
Equity925 m667 m512 m422 m293 m
Total assets1.1 bn822 m643 m549 m416 m
Operating cash flow-185 m-221 m-238 m-200 m-149 m
Investments (capex)21.4 m5.2 m1.5 m694,000386,000
Free cash-flow-206 m-226 m-239 m-201 m-150 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-1.31 x
Price / book value0.73 x
Return on Equity (ROE)-49.8 %
Return on Invested Capital (ROIC)-40.2 %
Net margin-3,760.0 %
Debt / equity0.17 x
Current ratio7.79 x
Interest coverage-142.48 x
Free cash-flow yield-38.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Allogene Therapeutics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
30 analysts

Breakdown of ratings

strong buy 0buy 19hold 10sell 1strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 11/10/2018
ISIN code
US0197701065
Workforce
226
full-time employees
Chief executive
David D. Chang

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Allogene Therapeutics, Inc.

What is the Allogene Therapeutics, Inc. share price?

Latest recorded price: 0.839 USD on 13/11/2026, for a market cap of 291 m USD.

What is the revenue of Allogene Therapeutics, Inc.?

22,000 USD for fiscal year 2024, with net income of -258 m USD (net margin -1,170,863.6 %).

What do analysts say about Allogene Therapeutics, Inc.?

Out of 30 analysts: 19 buy or strong buy, 10 hold, 1 sell or strong sell.

Is Allogene Therapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0197701065).

How many employees does Allogene Therapeutics, Inc. have?

226 full-time employees according to the latest published profile.

Who runs Allogene Therapeutics, Inc.?

David D. Chang is the company's chief executive.

07

Similar stocks